Evidence map›Paper›PMID 34233966›Full record

ArticleBMJ open2021

Study protocol of a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study).

Paxton Loke, Adriana Chebar Lozinsky, Francesca Orsini, Lydia Su-Yin Wong, Agnes Sze-Yin Leung, Elizabeth Huiwen Tham, Andreas L Lopata, Lynette Pei-Chi Shek, Mimi Lk Tang, PEAT study team

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Correlation and Agreement Between Parent-Report and Self-Report Food Allergy Quality of Life Questionnaires After Oral Immunotherapy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Paxton LokeAllergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia.ORCID 0000-0002-9474-083X
Adriana Chebar LozinskyAllergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia.ORCID 0000-0002-6765-2762
Francesca OrsiniClinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Lydia Su-Yin WongKhoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore.
Agnes Sze-Yin LeungAllergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Elizabeth Huiwen ThamKhoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore.
Andreas L LopataMolecular Allergy Research Laboratory, James Cook University College of Public Health Medical and Veterinary Sciences, Townsville, Queensland, Australia.
Lynette Pei-Chi ShekKhoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore.
Mimi Lk TangAllergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia mimi.tang@rch.org.au.
PEAT study team
Murdoch Children's Research Institute · AUNational University of Singapore · SGChinese University of Hong Kong · HKJames Cook University · AUNational University Health System · SGRoyal Children's Hospital · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEgg allergy is the most common food allergy in children but recent studies have shown persistence or delayed resolution into adolescence. As there is currently no effective long-term treatment, definitive treatments that improve quality of life and prevent fatalities for food allergies are required. We have previously shown that a novel treatment comprising a combination of the probiotic METHODS AND ANALYSIS: 80 participants aged 5-30 years of age with current egg allergy confirmed by double-blind placebo-controlled food challenge at study screening will be recruited from Australia and Singapore. There are two intervention arms-probiotic and egg OIT (active) or placebo. Interventions are administered once daily for 18 months. The primary outcome is the proportion of participants who attain 8-week sustained unresponsiveness in the active group versus placebo group. ETHICS AND DISSEMINATION: This study has been approved by the Human Research Ethics Committees at the Royal Children's Hospital (HREC 2019.082) and the National Healthcare Group Domain Specific Review Board (2019/00029). Results will be published in peer-reviewed journals and disseminated via presentations at international conferences. TRIAL REGISTRATION NUMBER: ACTRN12619000480189.

Indexed as

Egg HypersensitivityPeanut HypersensitivityProbioticsAdministration, OralAdolescentAllergensAustraliaChildClinical Trials, Phase II as TopicDesensitization, ImmunologicHumansQuality of LifeRandomized Controlled Trials as TopicSingaporeSoilTreatment OutcomeAllergensSoilAllergyClinical trialsIMMUNOLOGY

Identifiers

PMID34233966
PMCPMC8264865
OpenAlexW3178610766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.